Completed PHASE2 INTERVENTIONAL 2-arm NCT01642511

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative (IMSLNB-EBCP)

Phase II Trail of Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative

Sponsor: Shandong Cancer Hospital and Institute

Conditions Breast Cancer

Interventions 99mTc-labeled Sulfur Colloid Axillary Lymph Node Dissection Axillary Sentinel Lymph Node Biopsy Internal Mammary Sentinel Lymph Node Biopsy Lymphoscintigraphy Methylthioninium

Updated 6 times since 2017 Last updated: Apr 2, 2018 Started: Jan 31, 2012 Primary completion: Nov 30, 2014 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01642511, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Shandong Cancer Hospital and Institute, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — May 2018 [monthly]

Unknown Status PHASE2

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong Cancer Hospital and Institute

Data source: Shandong Cancer Hospital and Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China